Game-changing week for future patients with LA H&N SCC disease in England 🏴
✅Final NICE draft recommends periop pembro for PDL1+ resectable st III-IVa disease
📢Expected official publication: 20th April
@OncoAlert @brunolarvol @BAHNOOfficial
Long-Term Outcomes of Weekly Cisplatin Versus Carboplatin and Paclitaxel for Head and Neck Cancer | JCO Oncology Advances
Long-Term Outcomes of Weekly Cisplatin Versus Carboplatin and Paclitaxel for Head and Neck Cancer |...
PURPOSENational Comprehensive Cancer Network guidelines recommend weekly cisplatin and weekly carboplatin with paclitaxel as...
ascopubs.org
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study | Journal of Clinical Oncology
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and...
PURPOSEThe PD-1 inhibitor pembrolizumab is approved as first-line treatment for recurrent/metastatic head and neck squamou...
ascopubs.org
Game-changing week for future patients with LA H&N SCC disease in England 🏴
✅Final NICE draft recommends periop pembro for PDL1+ resectable st III-IVa disease
📢Expected official publication: 20th April
@OncoAlert @brunolarvol @BAHNOOfficial
Long-Term Outcomes of Weekly Cisplatin Versus Carboplatin and Paclitaxel for Head and Neck Cancer | JCO Oncology Advances
Long-Term Outcomes of Weekly Cisplatin Versus Carboplatin and Paclitaxel for Head and Neck Cancer |...
PURPOSENational Comprehensive Cancer Network guidelines recommend weekly cisplatin and weekly carboplatin with paclitaxel as...
ascopubs.org
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study | Journal of Clinical Oncology
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and...
PURPOSEThe PD-1 inhibitor pembrolizumab is approved as first-line treatment for recurrent/metastatic head and neck squamou...
ascopubs.org
Game-changing week for future patients with LA H&N SCC disease in England 🏴
✅Final NICE draft recommends periop pembro for PDL1+ resectable st III-IVa disease
📢Expected official publication: 20th April
@OncoAlert @brunolarvol @BAHNOOfficial
Long-Term Outcomes of Weekly Cisplatin Versus Carboplatin and Paclitaxel for Head and Neck Cancer | JCO Oncology Advances
Long-Term Outcomes of Weekly Cisplatin Versus Carboplatin and Paclitaxel for Head and Neck Cancer |...
PURPOSENational Comprehensive Cancer Network guidelines recommend weekly cisplatin and weekly carboplatin with paclitaxel as...
ascopubs.org
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study | Journal of Clinical Oncology
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and...
PURPOSEThe PD-1 inhibitor pembrolizumab is approved as first-line treatment for recurrent/metastatic head and neck squamou...
ascopubs.org
TTCC en cifras
